Immunoglobulin G (IgG) Subtype Is Associated with a Favorable Survival Prognosis in Patients Irradiated for Spinal Cord Compression from Myeloma

Dirk Rades, Antonio J. Conde-Moreno, Niklas Gebauer, Tobias Bartscht, Jon Cacicedo, Barbara Segedin, Steven E. Schild

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

AIM: This study was performed to investigate the prognostic impact of the myeloma subtype on the survival prognosis of patients with spinal cord compression (SCC) from myeloma.

PATIENTS AND METHODS: In 238 patients irradiated for SCC from myeloma, the myeloma subtype and 10 additional characteristics were evaluated for survival. These characteristics were fractionation of radiotherapy, age, time from myeloma diagnosis to SCC, presence of extra-osseous lesions, additional osseous lesions, gender, time to developing motor weakness, ability to walk, number of vertebrae affected by SCC and performance status.

RESULTS: Immunoglobulin G subtype was associated with significantly better survival than other subtypes both at 1 year (80% vs. 50%) and at 2 years (56% vs. 30%) following radiotherapy of SCC (p

CONCLUSION: This study identified myeloma subtype as being an independent prognostic factor of survival in patients with SCC from myeloma.

Original languageEnglish (US)
Pages (from-to)375-378
Number of pages4
JournalAnticancer Research
Volume36
Issue number1
StatePublished - Jan 1 2016

Fingerprint

Spinal Cord Compression
Immunoglobulin G
Survival
Radiotherapy
Spine

Keywords

  • Immunoglobulin G
  • myeloma
  • radiotherapy
  • spinal cord compression
  • survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rades, D., Conde-Moreno, A. J., Gebauer, N., Bartscht, T., Cacicedo, J., Segedin, B., & Schild, S. E. (2016). Immunoglobulin G (IgG) Subtype Is Associated with a Favorable Survival Prognosis in Patients Irradiated for Spinal Cord Compression from Myeloma. Anticancer Research, 36(1), 375-378.

Immunoglobulin G (IgG) Subtype Is Associated with a Favorable Survival Prognosis in Patients Irradiated for Spinal Cord Compression from Myeloma. / Rades, Dirk; Conde-Moreno, Antonio J.; Gebauer, Niklas; Bartscht, Tobias; Cacicedo, Jon; Segedin, Barbara; Schild, Steven E.

In: Anticancer Research, Vol. 36, No. 1, 01.01.2016, p. 375-378.

Research output: Contribution to journalArticle

Rades, D, Conde-Moreno, AJ, Gebauer, N, Bartscht, T, Cacicedo, J, Segedin, B & Schild, SE 2016, 'Immunoglobulin G (IgG) Subtype Is Associated with a Favorable Survival Prognosis in Patients Irradiated for Spinal Cord Compression from Myeloma', Anticancer Research, vol. 36, no. 1, pp. 375-378.
Rades, Dirk ; Conde-Moreno, Antonio J. ; Gebauer, Niklas ; Bartscht, Tobias ; Cacicedo, Jon ; Segedin, Barbara ; Schild, Steven E. / Immunoglobulin G (IgG) Subtype Is Associated with a Favorable Survival Prognosis in Patients Irradiated for Spinal Cord Compression from Myeloma. In: Anticancer Research. 2016 ; Vol. 36, No. 1. pp. 375-378.
@article{d4d68ead38d345888f19c7eed3a1893a,
title = "Immunoglobulin G (IgG) Subtype Is Associated with a Favorable Survival Prognosis in Patients Irradiated for Spinal Cord Compression from Myeloma",
abstract = "AIM: This study was performed to investigate the prognostic impact of the myeloma subtype on the survival prognosis of patients with spinal cord compression (SCC) from myeloma.PATIENTS AND METHODS: In 238 patients irradiated for SCC from myeloma, the myeloma subtype and 10 additional characteristics were evaluated for survival. These characteristics were fractionation of radiotherapy, age, time from myeloma diagnosis to SCC, presence of extra-osseous lesions, additional osseous lesions, gender, time to developing motor weakness, ability to walk, number of vertebrae affected by SCC and performance status.RESULTS: Immunoglobulin G subtype was associated with significantly better survival than other subtypes both at 1 year (80{\%} vs. 50{\%}) and at 2 years (56{\%} vs. 30{\%}) following radiotherapy of SCC (pCONCLUSION: This study identified myeloma subtype as being an independent prognostic factor of survival in patients with SCC from myeloma.",
keywords = "Immunoglobulin G, myeloma, radiotherapy, spinal cord compression, survival",
author = "Dirk Rades and Conde-Moreno, {Antonio J.} and Niklas Gebauer and Tobias Bartscht and Jon Cacicedo and Barbara Segedin and Schild, {Steven E.}",
year = "2016",
month = "1",
day = "1",
language = "English (US)",
volume = "36",
pages = "375--378",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Immunoglobulin G (IgG) Subtype Is Associated with a Favorable Survival Prognosis in Patients Irradiated for Spinal Cord Compression from Myeloma

AU - Rades, Dirk

AU - Conde-Moreno, Antonio J.

AU - Gebauer, Niklas

AU - Bartscht, Tobias

AU - Cacicedo, Jon

AU - Segedin, Barbara

AU - Schild, Steven E.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - AIM: This study was performed to investigate the prognostic impact of the myeloma subtype on the survival prognosis of patients with spinal cord compression (SCC) from myeloma.PATIENTS AND METHODS: In 238 patients irradiated for SCC from myeloma, the myeloma subtype and 10 additional characteristics were evaluated for survival. These characteristics were fractionation of radiotherapy, age, time from myeloma diagnosis to SCC, presence of extra-osseous lesions, additional osseous lesions, gender, time to developing motor weakness, ability to walk, number of vertebrae affected by SCC and performance status.RESULTS: Immunoglobulin G subtype was associated with significantly better survival than other subtypes both at 1 year (80% vs. 50%) and at 2 years (56% vs. 30%) following radiotherapy of SCC (pCONCLUSION: This study identified myeloma subtype as being an independent prognostic factor of survival in patients with SCC from myeloma.

AB - AIM: This study was performed to investigate the prognostic impact of the myeloma subtype on the survival prognosis of patients with spinal cord compression (SCC) from myeloma.PATIENTS AND METHODS: In 238 patients irradiated for SCC from myeloma, the myeloma subtype and 10 additional characteristics were evaluated for survival. These characteristics were fractionation of radiotherapy, age, time from myeloma diagnosis to SCC, presence of extra-osseous lesions, additional osseous lesions, gender, time to developing motor weakness, ability to walk, number of vertebrae affected by SCC and performance status.RESULTS: Immunoglobulin G subtype was associated with significantly better survival than other subtypes both at 1 year (80% vs. 50%) and at 2 years (56% vs. 30%) following radiotherapy of SCC (pCONCLUSION: This study identified myeloma subtype as being an independent prognostic factor of survival in patients with SCC from myeloma.

KW - Immunoglobulin G

KW - myeloma

KW - radiotherapy

KW - spinal cord compression

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84973409502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973409502&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 375

EP - 378

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -